Compassion for patients and excitement for scientific breakthroughs have always motivated me as an oncologist. I feel privileged to treat patients with challenging diseases with an expanding array of effective therapies.
Work and Credentials:
Primary Location
Other Location
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology, and Internal Medicine
Fellowship
University of North Carolina at Chapel Hill, Medical Oncology and Hematology; MD Anderson Cancer Center, Leukemia
Internship
The University of Texas Medical School at Houston
Residency
The University of Texas Medical School at Houston
Medical School
University of Virginia
College
University of Virginia
Special Interests
Gastrointestinal Cancers and Genitourinary Cancers
A graduate of the University of Virginia Medical School, Dr. Sampat completed his Internal Medicine residency at the University of Texas – Houston and then spent one year completing a Leukemia fellowship at MD Anderson Cancer Center. He completed his Hematology & Medical Oncology fellowship at the University of North Carolina. Dr. Sampat’s education and training reflect a particular interest in advancing treatment options for patients with gastrointestinal malignancies. He has contributed to several publications and presentations in this field. Dr. Sampat stays active in the medical community through his memberships in associations such as the American Society of Clinical Oncology and the American Society of Hematology.
In his spare time, Dr. Sampat enjoys hiking, bicycling, and traveling.
Physician Video:
'
Practice Blog
Physician Publications
February 1, 2013
Pleural effusions in patients with acute leukemia and myelodysplastic syndrome
Read MoreJune 1, 2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Read MoreMore Publications by Keeran R. Sampat, MD
January 1, 2011
Whole Gene Expression Profiling in Ankylosing Spondylitis Shows Upregulation of Toll-Like Receptor 4 and 5
Read MoreMay 15, 2010
Characteristics of pericardial effusions in patients with leukemia.
Read MoreOctober 1, 2009
Clofarabine: Emerging Role in Leukemias
Read MoreClinical Trials (6)
Clinical Trial Arcus Star-221
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Clinical Trial ARC-21
A safety and efficacy study of domvanalimab + zimberelimab combination therapy with and without chemotherapy in adult participants with advanced upper gastrointestinal tract malignancies
Clinical Trial GS-US-587-6156
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)
Clinical Trial 20341
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer (20-041-NCP)
Clinical Trial 21235
A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
Clinical Trial Xbiotech PT049
A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer
